Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cenegermin
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Dompe Farmaceutici
Deal Size : Undisclosed
Deal Type : Partnership
Tanner Pharma Group and Dompé Initiate Distribution Partnership for Oxervate®
Details : The agreement names Tanner Pharma Group as the exclusive provider of Oxervate (cenegermin) in countries outside of the United States, Canada, Italy, China and CIS countries (Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Russia, Tajikista...
Product Name : Oxervate
Product Type : Protein
Upfront Cash : Undisclosed
July 30, 2020
Lead Product(s) : Cenegermin
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Dompe Farmaceutici
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Clozapine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Tasmanian Alkaloids Pty Ltd
Deal Size : Undisclosed
Deal Type : Agreement
Tanner Pharma Group Signs Versacloz Distribution Agreement with Tasman Pharma Inc.
Details : Tanner to distribute Versacloz in areas outside of the U.S where the product is not yet registered. Versacloz is indicated for the treatment of severely ill patients with schizophrenia who fail to respond to standard antipsychotic treatment.
Product Name : Versacloz
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 22, 2020
Lead Product(s) : Clozapine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Tasmanian Alkaloids Pty Ltd
Deal Size : Undisclosed
Deal Type : Agreement